Alligator Bioscience announced the issuance of U.S. Patent No. 10,774,150 for its bispecific drug candidate, ATOR-1015, which targets CTLA-4 for metastatic cancer treatment. The patent protects this innovation until at least 2036, addressing challenges in immuno-oncology. Safety data from the ongoing Phase I clinical study were presented at ASCO in June 2020, with the study expected to conclude in Q4 2020 and a Phase Ib study planned for 2021.
Alligator Bioscience reported promising biomarker data from a Phase I study of mitazalimab, a CD40 antibody targeting pancreatic cancer. Results show significant gene upregulation, including PD-L1, which suggests the potential for enhanced tumor response to PD-1 therapy. The data supports a Phase II trial (OPTIMIZE-1) planned for December 2020, assessing mitazalimab in combination with chemotherapy. The study's findings were presented at the PEGS summit, indicating a stronger confidence in mitazalimab's efficacy and market potential.
Alligator Bioscience announced interim safety data for its drug candidate ATOR-1017, a 4-1BB antibody for treating metastasized cancer. The Phase I study showed a promising safety profile with few mild or moderate adverse events. The Data Review Committee has approved a higher dose of 100 mg for dosing. CEO Per Norlén expressed optimism about the drug's potential, highlighting its tolerability compared to typical 4-1BB therapies. A public R&D update is scheduled for Aug 27, 2020, to discuss further developments.
Alligator Bioscience (Nasdaq Stockholm: ATORX) will provide updates on its clinical drug candidates mitazalimab, ATOR-1015, and ATOR-1017 during a virtual R&D Day on August 27, 2020. Mitazalimab, targeting metastatic pancreatic cancer, will submit a Phase II clinical trial application by December 2020. Early signs of efficacy and safety were noted in prior studies. ATOR-1015 is advancing to Phase Ib studies for malignant melanoma with encouraging tolerability data. ATOR-1017 is in a Phase I study to activate T-cells for cancer treatment. Further details will be shared at the R&D Day.